Horizon Therapeutics completed the acquisition of the sterile fill‑finish manufacturing facility from EirGen Pharma for $65m.

Horizon Therapeutics, a biopharmaceutical company, completed the acquisition of the sterile fill‑finish manufacturing facility in Waterford, Ireland from EirGen Pharma, a subsidiary of OPKO Health, for $65 million. “The transaction with Horizon Therapeutics strengthens our balance sheet while reducing expenses and improving efficiency," Phillip Frost, M.D., OPKO Chairman & CEO.